Offering AmpliSeq V2 Panel through CLIA Lab, Mayo Pushes More Routine Cancer Sequencing | GenomeWeb

NEW YORK (GenomeWeb) — The Mayo Clinic last week announced that it will offer a test based on Ion Torrent's AmpliSeq V2 cancer hotspot panel through its CLIA-certified Next-Generation Sequencing Lab, a move that the clinic expects will routinize use of the 50-gene panel in the care of patients with a variety of solid tumors.

The AmpliSeq panel test, called CANCP, joins just one other NGS test, a 17-gene hereditary colon cancer assay, offered through the CLIA lab to Mayo physicians and to providers worldwide through the clinic's Mayo Medical Laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.